Navigation Links
Patients Who Know Their Gene Test Results are More Likely to Regularly Take and Remain on Statins, Study at ACC Shows
Date:3/26/2012

CHICAGO, March 26, 2012 /PRNewswire/ -- Genetic tests can help physicians more accurately diagnose and treat disease, but now there is evidence that these tests can also influence behavior -- motivating patients who are told of their test results to regularly take and stay on medications to treat high cholesterol.  The results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) study was presented today by investigators from the Medco Research Institute™, a subsidiary of Medco Health Solutions, Inc. (NYSE: MHS) and Quest Diagnostics (NYSE: DGX), the world's leading diagnostic testing company, at the American College of Cardiology's 61st Annual Scientific Session & Expo. 

(Logo:  http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO )

The study found that patients who were provided written information about their kinesin-like protein 6 (KIF6) gene test improved their overall adherence to statin therapy over six months, the study's primary end point, by 13 percent compared to those that had not received the gene test.

"Medication adherence is an extremely important global issue in patient care, and in particular for evidence-based therapies that help to lower cholesterol and reduce the risk and cost burden of cardiovascular disease, including heart attack and stroke," said Dr. Scott Charland, senior director from the Medco Research Institute (MRI) and study principal investigator.  "This is the first prospective study to show that genetic testing, and subsequently providing patients their test results, has clinical utility through improving adherence to a specific drug therapy -- a finding that could open-up a whole new way of thinking about the benef
'/>"/>

SOURCE Medco Health Solutions, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. OptiScan Biomedical Presents Study Results Demonstrating OptiScanners Excellent Glucose Monitoring Accuracy in Critically Ill ICU Patients
2. Medco Study Finds Many Patients on Newer Oncology Treatments Are at Risk for Drug Interactions
3. Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer
4. Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushings disease patients in Phase III study
5. Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx
6. Physicians Order Costly, Redundant Neuroimaging for Stroke Patients, Study Says
7. Study Published in Molecular Therapy Shows that Immune Response to FANG™ Personalized Cancer Therapeutic Correlates with Prolonged Survival in Patients with Advanced Stage Cancer
8. Polaris Group Doses First Patient in Phase 1 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 in Pediatric Patients with Emphasis on Leukemia, Lymphoma and Sarcoma
9. U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
10. Ameritox Supports New Expert Consensus Recommendations For Patients on Long-Term Opioid Therapy
11. Study Links the Risk of Hypogonadism in Men to Long Acting Opioids in Patients Using Daily Opioid Therapy for Chronic Noncancer Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... Intelomed is pleased to announce that ... as the Vice President of Clinical Affairs. With over ... device industry, Kay,s experience in taking medical technology and ... to global expansion, is a valuable addition to the ... on our team, and I am confident her focused ...
(Date:8/26/2014)... , Aug. 26, 2014 Blue Bell, Pennsylvania ... office worldwide. PRA, a leading global Contract Research Organization (CRO), is ... Fort Washington locations into new modern Class A+ ... office opened this week and marks the first phase of the ... us at PRA," said Harris Koffer , President of the ...
(Date:8/26/2014)... comes to diabetes supplies, innovations are often accused of ... answer a real medical need. Fitting ... shows how long it,s been since your last injection. ... insulin doses. Very easy to use, Timesulin starts automatically ... after an injection. There is no settings or complicated ...
Breaking Medicine Technology:Mary Kay Deck joins Intelomed as Vice President of Clinical Affairs 2PRA Health Sciences Expands in Pennsylvania 2Montméd obtains reimbursement of Timesulin, the smart insulin pen timer cap, by major insurance companies in Canada 2
(Date:8/27/2014)... Chicago, Illinois (PRWEB) August 27, 2014 ... integration project in the US with Buzz™ Digital O.R. ... The foundation of all 13 new operating rooms will ... control and management. This integrative system supports planning, navigation, ... is an advanced fusion of intuitive software and hardware ...
(Date:8/27/2014)... August 27, 2014 SCOTT Sports ... Park, Utah’s first indoor mountain bike and BMX park. ... park-style bikes in both adult and youth sizes for the ... operated a distribution warehouse in Ogden, Utah, recently moved its ... , “We are proud to be a partner with the ...
(Date:8/27/2014)... Steven Reinberg HealthDay Reporter ... hormone used to reduce the need for blood transfusions might ... suggests. Synthetic erythropoietin (EPO), which stimulates red blood cell ... preterm birth, said lead researcher Dr. Petra Huppi, a professor ... in Switzerland. "The real test of whether EPO protects ...
(Date:8/27/2014)... microGUNE, the Co-operative Research Centre into Microtechnologies, ... to generate innovative solutions based on microtechnologies ... industry and life sciences, among others. IK4-Ikerlan, ... are collaborating with CIC microGUNE on this ... by the Etortek 2013-2014 programme of the ...
(Date:8/27/2014)... water and oil and are persistent towards aggressive ... characteristics have made the fluorochemicals useful in numerous ... paper and board. , The problem with fluorochemicals ... and accumulate in both humans and the environment. ... effects, such as cancer, increased cholesterol and a ...
Breaking Medicine News(10 mins):Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 2Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 3Health News:SCOTT Sports to Sponsor Wasatch Indoor Bike Park 2Health News:Hormone Might Help Preemies' Brains 2Health News:Hormone Might Help Preemies' Brains 3Health News:Microtechnologies for driving forward mobility and human health 2Health News:Leading scientists call for a stop to non-essential use of fluorochemicals 2Health News:Leading scientists call for a stop to non-essential use of fluorochemicals 3
... many aren,t getting preventive treatments , , THURSDAY, Jan. ... patients in hospitals worldwide risk developing dangerous blood ... receiving treatments that could prevent the condition, a ... long been recognized to be one of the ...
... NEW YORK, Jan. 31 QED International Associates, ... 20 underlying,indexes for the HealthShares(TM) Exchange-Traded Funds, today ... Monday February 4, 2008,BioMerieux Worldwide (Euronext: BIM) will ... European Medical Products and Devices Index., Companies ...
... But analysis calls gap between these and lower-tier facilities ... admitted to the top-rated hospitals in the United States ... than patients admitted to other hospitals in the country, ... an independent health-care ratings organization, the analysis of 27 ...
... Set for February 29, 2008, PALO ALTO, ... JAZZ ) announced today that the U.S. Food ... submission of the,response by Solvay Pharmaceuticals, Inc. to ... maleate) Extended-Release Capsules. The,FDA has notified Solvay Pharmaceuticals ...
... N.J., Jan. 31 Medarex, Inc.,(Nasdaq: MEDX ) ... the,Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device,Conference at ... event will be,webcast live and will be available in ... http://www.medarex.com . An archived edition of the,presentation will ...
... Jan. 31 Acura,Pharmaceuticals, Inc. (OTC Bulletin Board: ... Market(R) has approved the Company,s application to,list its ... The,Company,s common stock will commence trading on NASDAQ ... "We are pleased to join the growing ...
Cached Medicine News:Health News:Hospital Patients' Blood Clot Risk High 2Health News:Hospital Patients' Blood Clot Risk High 3Health News:Top-Rated Hospitals Continue to Deliver Better Care 2Health News:Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR 2Health News:Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference 2Health News:Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR 2
... Graham-Field has been developing diverse ... 58 years. Our medical-surgical products ... for innovation, quality and customer ... include the Labtron® line of ...
Kit Nebulizer Small Volume Medication W/Pediatric Mask Mouthpiece 7FT O 2 Tubing...
... Small Volume Medication Mouthpiece 7FT O 2 ... advanced jet design for fast treatment times , ... a tighter distribution (higher percentage of respirable particles) ... AirLife™ brand Misty Max 10™ disposable nebulizers deliver ...
... Products, ,Westmed designs, manufacturers and markets ... Respiratory professionals. Our mission is to design ... ability to deliver quality medical care while ... , ,Our web site is designed ...
Medicine Products: